rs115860688 (MYO1B-AS1): Blood Biomarker Variant

Key takeaways

• rs115860688 sits near MYO1B-AS1, a non-coding antisense RNA gene, and was flagged in one of the largest blood biomarker genetic studies ever conducted.
• The study that identified this variant included over 363,000 individuals from the UK Biobank, across five ancestry groups.
• The broader study found over 3,000 fine-mapped genetic associations across 35 biomarkers, placing this variant in a well-powered discovery context.
• No lifestyle, drug-response, or tissue-expression data specific to this variant are available in the provided evidence base.

What the research says rs115860688, located near MYO1B-AS1 (myosin IB antisense RNA 1, a non-coding RNA gene transcribed in the opposite direction from MYO1B), was identified in a genome-wide association study of 35 blood and urine biomarkers in the UK Biobank (n=363,228 unrelated individuals), with meta-analysis spanning White British (n=318,953), non-British White (n=23,582), African (n=6,019), South Asian (n=7,338), and East Asian (n=1,082) population groups (total meta-analysis n=355,891). The study applied Bonferroni-corrected significance thresholds (p < 5 x 10^-9 for assayed and imputed variants) and fine-mapped 3,374 associations across 1,857 loci, with linkage disequilibrium score intercepts between 0.999 and 1.137 across all phenotypes, indicating well-controlled population stratification. The specific biomarker trait and effect size attributed to this locus are not reproduced in the available study excerpt.

Reported associations

• Specific biomarker (not stated in available text): rs115860688 was identified among 3,374 fine-mapped associations across 35 blood and urine biomarkers in the UK Biobank; the exact trait and effect size for this locus are not reproduced in the provided source text.

Evidence quality The source study is large (primary analysis n=363,228; meta-analysis n=355,891) and applied stringent Bonferroni-corrected thresholds (p < 5 x 10^-9). Fine-mapping was performed to prioritize probable causal variants, and analysis spanned five ancestry groups. Polygenic risk scores derived from the same study improved disease risk prediction for chronic kidney disease, type 2 diabetes, gout, and alcoholic cirrhosis in an independent dataset (FinnGen, n=135,500), demonstrating external validity for the broader discovery effort. However, the specific association data for this locus, including its associated biomarker, effect size, and independent replication status, are not reproduced in the available study text, so the strength of evidence for this individual variant cannot be fully characterized here. This entry should be considered preliminary pending review of the full study association tables.

Lifestyle considerations No lifestyle considerations on file for this variant.